Natco Pharma Ltd's Q4FY25 Quarter Results
- 29 May 2025
Result Summary
- Natco Pharma Ltd reported a 70.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 19.8%.
- Its expenses for the quarter were up by 29.8% QoQ and 5.0% YoY.
- The net profit increased 191.8% QoQ and increased 40.1% YoY.
- The earnings per share (EPS) of Natco Pharma Ltd stood at 21.6 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1110.30 | 651.10 | 926.90 | 70.5% | 19.8% |
Total Expenses | 632.70 | 487.40 | 602.50 | 29.8% | 5.0% |
Profit Before Tax | 477.60 | 163.70 | 324.40 | 191.8% | 47.2% |
Tax | 91.30 | 31.30 | 48.60 | 191.7% | 87.9% |
Profit After Tax | 386.30 | 132.40 | 275.80 | 191.8% | 40.1% |
Earnings Per Share | 21.60 | 7.40 | 15.10 | 191.9% | 43.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Natco Pharma Ltd is a well-established pharmaceutical company primarily engaged in the development, manufacturing, and marketing of generic pharmaceuticals. The company is known for its expertise in oncology and niche therapeutic areas, including cardiovascular and central nervous system diseases. Natco Pharma has a significant presence in both the domestic and international markets, with a strong portfolio of products that cater to a diverse range of medical needs. While the company continues to focus on expanding its product pipeline and enhancing its manufacturing capabilities, specific recent developments about Natco Pharma's operations or strategic initiatives were not provided in the available data.
Revenue
During the fourth quarter of the fiscal year 2025 (Q4FY25), Natco Pharma Ltd reported a total income of ₹1,110.30 crores. This represents a significant increase of 70.5% quarter-over-quarter (QoQ) from ₹651.10 crores in Q3FY25 and a year-over-year (YoY) increase of 19.8% from ₹926.90 crores in Q4FY24. The substantial growth in total income indicates an improvement in the company's revenue generation over both the previous quarter and the same quarter of the prior year. This uptick in revenue can be attributed to various factors that are not detailed in the provided data.
Profitability
Natco Pharma Ltd's profitability improved markedly in Q4FY25. The company recorded a profit before tax of ₹477.60 crores, which is a 191.8% increase QoQ from ₹163.70 crores in Q3FY25 and a 47.2% increase YoY from ₹324.40 crores in Q4FY24. The profit after tax for Q4FY25 stood at ₹386.30 crores, reflecting a 191.8% increase QoQ from ₹132.40 crores and a 40.1% increase YoY from ₹275.80 crores. The company's tax expenses also rose to ₹91.30 crores in Q4FY25, which is a 191.7% increase QoQ from ₹31.30 crores and an 87.9% increase YoY from ₹48.60 crores. Additionally, the earnings per share (EPS) for Q4FY25 was ₹21.60, marking a 191.9% increase QoQ from ₹7.40 and a 43.0% increase YoY from ₹15.10.
Operating Metrics
In Q4FY25, Natco Pharma Ltd's total expenses amounted to ₹632.70 crores, which is a growth of 29.8% compared to the previous quarter's ₹487.40 crores and a 5.0% increase from ₹602.50 crores in the same quarter of the previous year. The company demonstrated a robust operating performance, with a notable rise in both income and expenses, suggesting efficient management of operational activities. The data does not provide specific information on other operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio, which limits the analysis of certain financial aspects. However, the overall financial data reflects a strong quarterly performance in terms of income and profitability growth.